Forma Therapeutics Holdings, Inc.

2022 Q2 Form 10-Q Financial Statement

#000095017022008130 Filed on May 06, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q1

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $395.9M $421.4M $550.7M
YoY Change -26.08% -23.49% 286.73%
Cash & Equivalents $75.14M $74.42M $97.83M
Short-Term Investments $320.8M $346.9M $452.9M
Other Short-Term Assets $15.17M $11.42M $8.100M
YoY Change 112.78% 40.96% 145.45%
Inventory
Prepaid Expenses $6.065M
Receivables
Other Receivables
Total Short-Term Assets $426.4M $446.5M $573.9M
YoY Change -23.57% -22.19% 224.97%
LONG-TERM ASSETS
Property, Plant & Equipment $13.64M $13.55M $1.420M
YoY Change 928.28% 854.23% -35.45%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $19.99M $53.00M
YoY Change -100.0% -62.29%
Other Assets $12.84M $12.82M $15.00M
YoY Change -14.56% -14.55% 11.11%
Total Long-Term Assets $48.72M $67.97M $76.30M
YoY Change -12.12% -10.91% 382.91%
TOTAL ASSETS
Total Short-Term Assets $426.4M $446.5M $573.9M
Total Long-Term Assets $48.72M $67.97M $76.30M
Total Assets $475.2M $514.5M $650.2M
YoY Change -22.53% -20.87% 237.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.040M $2.044M $2.900M
YoY Change -39.39% -29.52% 45.0%
Accrued Expenses $25.05M $19.09M $26.71M
YoY Change 3.98% -28.51% 39.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $33.46M $26.34M $28.60M
YoY Change 7.6% -7.91% 30.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $27.21M $26.97M $5.200M
YoY Change 846.87% 418.6% 205.88%
Total Long-Term Liabilities $27.21M $26.97M $5.200M
YoY Change 846.87% 418.6% 205.88%
TOTAL LIABILITIES
Total Short-Term Liabilities $33.46M $26.34M $28.60M
Total Long-Term Liabilities $27.21M $26.97M $5.200M
Total Liabilities $60.68M $53.30M $33.80M
YoY Change 78.6% 57.7% 43.22%
SHAREHOLDERS EQUITY
Retained Earnings -$327.1M -$274.5M
YoY Change 138.84%
Common Stock $741.6M $735.7M
YoY Change 3.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $414.5M $461.2M $616.5M
YoY Change
Total Liabilities & Shareholders Equity $475.2M $514.5M $650.2M
YoY Change -22.53% -20.87% 237.94%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001538927
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 fmtx Public Offering Costs Included In Accounts Payable And Accrued Expenses
PublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-39333
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Forma Therapeutics Holdings, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
37-1657129
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
300 North Beacon Street
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 501
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2022Q1 dei City Area Code
CityAreaCode
617
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
679-1970
CY2022Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
FMTX
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47804697
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74415000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77421000
CY2022Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
346943000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
386805000
CY2022Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
12050000
CY2021Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
11988000
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
735678000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13117000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10187000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
446525000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
486401000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13550000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13927000
CY2022Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
19985000
CY2021Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
26047000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
21620000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
22074000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12817000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12612000
CY2022Q1 us-gaap Assets
Assets
514497000
CY2021Q4 us-gaap Assets
Assets
561061000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2044000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4145000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19091000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25748000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5112000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5125000
CY2022Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
90000
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
70000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
26337000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
35088000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
26967000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27617000
CY2022Q1 us-gaap Liabilities
Liabilities
53304000
CY2021Q4 us-gaap Liabilities
Liabilities
62705000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47771388
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47411356
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47762683
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47398238
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
47000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
47000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-44158000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
254000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
258000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44155000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35952000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
616465000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-35960000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
638000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
728683000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-274532000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-230374000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
461193000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
498356000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
514497000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
561061000
CY2022Q1 us-gaap Revenues
Revenues
0
CY2021Q1 us-gaap Revenues
Revenues
0
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31273000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26343000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13136000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9867000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
44409000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
36210000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-44409000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-36210000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
289000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
262000
CY2022Q1 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-35000
CY2021Q1 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
-4000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-35960000
CY2022Q1 fmtx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-44158000
CY2021Q1 fmtx Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-35960000
CY2022Q1 fmtx Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.93
CY2021Q1 fmtx Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.76
CY2022Q1 fmtx Weightedaveragenumberofbasicanddilutedsharesoutstanding
Weightedaveragenumberofbasicanddilutedsharesoutstanding
47561631
CY2021Q1 fmtx Weightedaveragenumberofbasicanddilutedsharesoutstanding
Weightedaveragenumberofbasicanddilutedsharesoutstanding
47295013
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
648244000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
333000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3848000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-35960000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
498356000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
741000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6254000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-44158000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
461193000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-44158000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
183000
CY2022Q1 fmtx Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
261000
CY2021Q1 fmtx Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
375000
CY2022Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
6254000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2930000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1954000
CY2021Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
3848000
CY2022Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-2000
CY2021Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
377000
CY2022Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-62000
CY2021Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
207000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2555000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2138000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1368000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6708000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3990000
CY2022Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
20000
CY2021Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
73000
CY2022Q1 fmtx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-470000
CY2021Q1 fmtx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-473000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-49295000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41237000
CY2022Q1 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
148905000
CY2021Q1 us-gaap Payments To Acquire Held To Maturity Securities
PaymentsToAcquireHeldToMaturitySecurities
257868000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
194831000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
114500000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
261000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
83000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45665000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-143451000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
741000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
333000
CY2022Q1 fmtx Payment Of Public Offering Costs
PaymentOfPublicOfferingCosts
-79000
CY2021Q1 fmtx Payment Of Public Offering Costs
PaymentOfPublicOfferingCosts
-500000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
662000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-167000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2968000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-184855000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
79538000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
285159000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76570000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100304000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
7478000
CY2022Q1 fmtx Public Offering Costs Included In Accounts Payable And Accrued Expenses
PublicOfferingCostsIncludedInAccountsPayableAndAccruedExpenses
111000
CY2020Q4 fmtx Follow On Public Offering Price Per Share
FollowOnPublicOfferingPricePerShare
45.25
CY2020Q4 fmtx Proceeds From Follow On Offering After Deducting Expenses
ProceedsFromFollowOnOfferingAfterDeductingExpenses
258600000
CY2021Q3 fmtx Aggregate Amount Of Issuance And Offering Cost
AggregateAmountOfIssuanceAndOfferingCost
200000000.0
CY2021Q3 fmtx Common Stock Under The2021 Shelf
CommonStockUnderThe2021Shelf
150000000.0
CY2021Q3 fmtx Sales Agent Cash Commissions
SalesAgentCashCommissions
0.030
CY2022Q1 fmtx Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
441300000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
2155000
CY2021Q1 us-gaap Restricted Cash
RestrictedCash
2470000
CY2022Q1 fmtx Short Term Highly Liquid Investments With Original Maturities
ShortTermHighlyLiquidInvestmentsWithOriginalMaturities
90 days or less
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76570000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
100304000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74415000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97834000
CY2022Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
436186000
CY2022Q1 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
366928000
CY2022Q1 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
0
CY2022Q1 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
1478000
CY2022Q1 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
365450000
CY2021Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
412852000
CY2021Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
38000
CY2021Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
204000
CY2021Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
412686000
CY2022Q1 fmtx Aggregate Fair Value Unrealized Loss Position
AggregateFairValueUnrealizedLossPosition
365500000
CY2021Q4 fmtx Aggregate Fair Value Unrealized Loss Position
AggregateFairValueUnrealizedLossPosition
219300000
CY2022Q1 fmtx Manufacturing And Clinical Prepaid Expenses
ManufacturingAndClinicalPrepaidExpenses
7451000
CY2021Q4 fmtx Manufacturing And Clinical Prepaid Expenses
ManufacturingAndClinicalPrepaidExpenses
5559000
CY2022Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3967000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3549000
CY2022Q1 us-gaap Other Receivables
OtherReceivables
1699000
CY2021Q4 us-gaap Other Receivables
OtherReceivables
1079000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13117000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10187000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18785000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18696000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5235000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4769000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13550000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13927000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2022Q1 fmtx Operating Lease Monthly Base Rent Expense
OperatingLeaseMonthlyBaseRentExpense
100000
CY2022Q1 fmtx Annual Percentage Increase In Base Rent
AnnualPercentageIncreaseInBaseRent
0.030
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
971000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1195000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1464000
CY2022Q1 fmtx Accrued Expenses And Other Liabilities Current Net
AccruedExpensesAndOtherLiabilitiesCurrentNet
19091000
CY2021Q4 fmtx Accrued Expenses And Other Liabilities Current Net
AccruedExpensesAndOtherLiabilitiesCurrentNet
25748000
CY2022Q1 fmtx Manufacturing And Clinical Accruals
ManufacturingAndClinicalAccruals
9382000
CY2021Q4 fmtx Manufacturing And Clinical Accruals
ManufacturingAndClinicalAccruals
11001000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4503000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8508000
CY2022Q1 fmtx Other Research And Development Related Accruals
OtherResearchAndDevelopmentRelatedAccruals
2867000
CY2021Q4 fmtx Other Research And Development Related Accruals
OtherResearchAndDevelopmentRelatedAccruals
3804000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1144000
CY2022Q1 fmtx Cost For Guarantees And Indemnities
CostForGuaranteesAndIndemnities
0
CY2021Q4 fmtx Cost For Guarantees And Indemnities
CostForGuaranteesAndIndemnities
0
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.25
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12179058
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6254000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3848000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6254000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3848000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5942569
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.12
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
33891000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
881690
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.08
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
131788
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
50887
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
25.17
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.798
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.780
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6641584
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.69
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y3M18D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
14696000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2827068
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.87
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y8M12D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
8709000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6641584
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
13.69
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
14696000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0180
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0094
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D

Files In Submission

Name View Source Status
0000950170-22-008130-index-headers.html Edgar Link pending
0000950170-22-008130-index.html Edgar Link pending
0000950170-22-008130.txt Edgar Link pending
0000950170-22-008130-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
fmtx-20220331.htm Edgar Link pending
fmtx-20220331.xsd Edgar Link pending
fmtx-20220331_cal.xml Edgar Link unprocessable
fmtx-20220331_def.xml Edgar Link unprocessable
fmtx-20220331_htm.xml Edgar Link completed
fmtx-20220331_lab.xml Edgar Link unprocessable
fmtx-20220331_pre.xml Edgar Link unprocessable
fmtx-ex31_1.htm Edgar Link pending
fmtx-ex31_2.htm Edgar Link pending
fmtx-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending